Patent RU-2767652-C2 (RU)
Title: New compounds
Inventor: PORRAS DE FRANCISCO ESTHER
IPC: A61K31/501
Filed: 2018-08-15
Granted: 2022-03-18
Abstract: FIELD: pharmaceutics.SUBSTANCE: invention relates to organic compounds. Disclosed is a compound or a pharmaceutically acceptable salt thereof, selected from the following compounds: 4,4,4-trifluoro-1-[4-fluoro-4-(3-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-(5-fluoro-3-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-(6-fluoro-3-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-[6-(trifluoromethyl)-3-pyridyl]-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-[4-(trifluoromethyl)-2-pyridyl]-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-[5-(trifluoromethyl)-3-pyridyl]-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-[6-(trifluoromethyl)-2-pyridyl]-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-(6-fluoro-2-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-(6-methoxy-3-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-[2-(trifluoromethyl)-3-pyridyl]-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-(5-methoxy-3-pyridyl)-1-piperidyl] butan-1-one; 1-[4-(3,5-difluoro-2-pyridyl)-1-piperidyl]-4,4,4-trifluoro-butan-1-one; 1-[4-(2,6-difluoro-3-pyridyl)-1-piperidyl]-4,4,4-trifluoro-butan-1-one; 4,4,4-trifluoro-1-[4-(5-fluoro-2-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-(4-(2-(trifluoromethyl)pyridin-4-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1-(4-(2-fluoropyridin-4-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1-(4-(5-(trifluoromethyl)pyrazin-2-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1-(4-(2-methylpyridin-4-yl)piperidin-1-yl)butan-1-one; 1-(4-(5,6-difluoropyridin-3-yl)piperidin-1-yl)-4,4,4-trifluorobutan-1-one; 4,4,4-trifluoro-1-(4-(6-(trifluoromethyl)pyrazin-2-yl)piperidin-1-yl)butan-1-one; 1-(4-(2-chloropyridin-4-yl)piperidin-1-yl)-4,4,4-trifluorobutan-1-one; 4,4,4-trifluoro-1-(4-(3-fluoropyridin-4-yl)piperidin-1-yl)butan-1-one; 1-(4-(6-chloropyridin-2-yl)piperidin-1-yl)-4,4,4-trifluorobutan-1-one; 1-(4-(5-chloropyridin-3-yl)-4-fluoropiperidin-1-yl)-4,4,4-trifluorobutan-1-one; 1-(4-(5-chloropyridin-3-yl)piperidin-1-yl)-4,4,4-trifluorobutan-1-one; 1-(4-(5-chloropyridin-3-yl)piperidin-1-yl)-5,5,5-trifluoropentan-1-one; 1-(4-(6-chloropyrazin-2-yl)piperidin-1-yl)-4,4,4-trifluorobutan-1-one; 4,4,4-trifluoro-1-(4-fluoro-4-(pyridin-2-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1-(4-fluoro-4-(5-(trifluoromethyl)pyridin-3-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1-(4-fluoro-4-(2-(trifluoromethyl)pyridin-4-yl)piperidin-1-yl)butan-1-one; 1-(4-(6-chloropyrazin-2-yl)-4-fluoropiperidin-1-yl)-4,4,4-trifluorobutan-1-one; 4,4,4-trifluoro-1-(4-fluoro-4-(2-fluoropyridin-4-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1- [4-fluoro-4- [4-(trifluoromethyl)-2-pyridyl]-1-piperidyl] butan-1-one; 1-(3-(5-chloropyridin-3-yl)pyrrolidin-1-yl)-4,4,4-trifluorobutan-1-one; and 1-[4-(2-chloro-4-pyridyl)-4-fluoro-1-piperidyl]-4,4,4-trifluoro-butan-1-one. Also disclosed is a pharmaceutical composition and a combination containing said compound, use and methods of treating mycobacterial infection and disease caused byMycobacterium tuberculosisinfection.EFFECT: development of new compounds applicable in treating mycobacterial infections and diseases caused by mycobacteria.14 cl, 14 tbl, 41 ex